$IBRX says it has the holy grail of medicine. That is, a drug that cures cancer. No chemo needed....
Twitter
Note: AI-generated summary based on third-party content. Not financial advice. Read more.
Quick Insights
ImmunityBio ($IBRX) presents a high-risk, high-reward opportunity based on the potential FDA approval of its cancer drug, ANKTIVA. The drug, described as a "holy grail" that cures cancer without chemotherapy, activates natural killer cells, CD8+ killer T cells, and drives memory T cells to recognize cancer over time. A successful approval could lead to a 100x return or more, making it a binary bet on the upcoming FDA decision.
Ask about this postAnswers are grounded in this post's content.
Tweet
About Beanie
Beanie
By beaniemaxi
Crypto native since the early days. Went all in on DeFi summer. Then tripled down on NFTs. VC @gmcapital_. No paid promos. Not financial advice. I talk my book.